E. Kimby
AuthID: R-00F-FGC
1
TITLE: TIME TO NEXT ANTI-LYMPHOMA THERAPY (TTNT) AND TREATMENT-FREE INTERVAL (TFI) WITH BORTEZOMIB-RITUXIMAB (VCR) VS RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL)
AUTHORS: Kimby, E; Scheliga, A; Mayer, J; Offner, F; Teixeira, A; Kuliczkowski, K; Liberati, AM; Okada, CY; Esseltine, D; Theocharous, P; Zhu, E; Van de Velde, H; Elsayed, YA; Coiffier, B;
PUBLISHED: 2011, SOURCE: 11th International Conference on Malignant Lymphoma in ANNALS OF ONCOLOGY, VOLUME: 22
AUTHORS: Kimby, E; Scheliga, A; Mayer, J; Offner, F; Teixeira, A; Kuliczkowski, K; Liberati, AM; Okada, CY; Esseltine, D; Theocharous, P; Zhu, E; Van de Velde, H; Elsayed, YA; Coiffier, B;
PUBLISHED: 2011, SOURCE: 11th International Conference on Malignant Lymphoma in ANNALS OF ONCOLOGY, VOLUME: 22
INDEXED IN: 
WOS
WOS